Heron Therapeutics Inc. (HRTX) 10.29 $HRTX
Heron Therapeutics to complete Phase 1 clinical study of HTX-011 for post-operative pain in Q1 and begin Phase 1b/2 studies in surgical patients in Q2
M2 - Thu Feb 12, 4:51AM CST
Biotechnology company Heron Therapeutics (NasdaqCM:HRTX) disclosed on Wednesday the launch of a Phase 1 clinical trial of HTX-011 for the treatment of post-operative pain.
HRTX: 10.29 (+0.39)
Heron Therapeutics Initiates Phase 1 Clinical Study of HTX-011 for the Treatment of Post-Operative Pain
Business Wire - Wed Feb 11, 7:02AM CST
---Phase 1b/2 studies in surgical patients to start in second quarter
HRTX: 10.29 (+0.39)
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 10, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
LGCY: 13.35 (+0.51), AMKR: 8.90 (-0.02), EPRS: 7.67 (+0.67), MFLX: 14.99 (+0.16), MGPI: 14.00 (-0.39), GFN: 9.20 (+0.25), EGLT: 10.60 (+0.58), HRTX: 10.29 (+0.39), PFMT: 6.02 (-0.02), ACHN: 10.89 (-0.20), AGIO: 118.55 (+0.11), QLYS: 47.95 (+1.46), YDLE: 13.07 (+1.14), CBMG: 24.32 (-1.17)
Heron Therapeutics to Present at the Leerink Partners 2015 Global Healthcare Conference
Business Wire - Tue Feb 03, 7:02AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Leerink Partners 2015 Global Healthcare Conference on Wednesday, February 11, 2015 at 8:50 a.m. ET in New York City.
HRTX: 10.29 (+0.39)
Medical chief bids adieu at Heron
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 3:56PM CST
HRTX: 10.29 (+0.39)
Global CINV Existing and Pipeline Drugs (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) Market 2014 - 2020
M2 - Wed Jan 14, 9:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/8zvsf9/cinv_existing_and) has announced the addition of the "CINV Existing and Pipeline Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The approval of new drugs such as rolapitant and SUSTOL (APF-530) would also drive the growth of the CINV drugs market during the forecast period from 2014 to 2020. These pipeline drugs have shown better efficacy than existing drugs during their clinical study. Therefore, the anticipated launch of these more efficacious pipeline drugs during the projected period is likely to encourage physicians to prescribe these new drugs over existing drugs. H owever, the patent expiry of leading drugs Aloxi and Emend are expected to have significant impact on the revenue of overall CINV drugs market during the forecast period from 2014 to 2020. North America was the largest regional market for CINV drugs in 2013 in terms of revenue and is expected to retain its position throughout the forecast period, primarily due to the anticipated approval of rolapitant and SUSTOL in 2015 and 2016, respectively. Europe represented the second largest market for CINV drugs after North America in 2013. The launch of CINV pipeline drugs in Europe is expected to be a year later than in North America, given the delays on the past launches of CINV drugs such as Aloxi and Emend. The high incidence of various types of cancer in Asia-Pacific and Rest of the World (RoW) represents both these regions as potential markets for CINV drugs. The economic emergence of countries such as India and China, along with their continuously improving health care infrastructure, is expected to play a key role in driving the CINV market growth in Asia-Pacific region. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global CINV Existing and Pipeline Drugs Market Overview Chapter 4 Global CINV Existing and Pipeline Drugs Market Revenue, by Major Drugs, 2012 - 2020 (USD Million) Chapter 5 Global CINV Existing and Pipeline Drugs Market Revenue, by Geography, 2012 - 2020 (USD Million) Chapter 6 Competitive Landscape Chapter 7 Company Profiles - GlaxoSmithKline plc - Helsinn Holding S.A. - Heron Therapeutics, Inc. - Merck & Co., Inc. - Tesaro, Inc. For more information visit http://www.researchandmarkets.com/research/8z...isting_and
TSRO: 38.49 (-0.83), HRTX: 10.29 (+0.39), MRK: 58.81 (-0.07), GSK: 47.94 (+1.99)
Conkwest Appoints Robert Rosen and Henry Ji to its Board of Directors
Business Wire - Mon Dec 29, 1:40PM CST
Conkwest, Inc. (the Natural Killer Cell Company of the West), an immuno-oncology company developing Neukoplast(TM) (NK-92(TM)), a proprietary Natural Killer (NK) cell-line based therapy, announces the appointments of Robert Rosen and Henry Ji, Ph.D. to the Company's Board of Directors. Mr. Rosen is President of Heron Therapeutics (NASDAQ:HRTX) and Dr. Ji is co-founder, President and CEO of Sorrento Therapeutics, Inc. (NASDAQ:SRNE).
HRTX: 10.29 (+0.39), LJPC: 18.79 (unch), SRNE: 11.41 (+0.56)
5 Stocks Under $10 Setting Up to Trade Higher: Covisint and More
at The Street - Thu Dec 11, 11:46AM CST
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
HRTX: 10.29 (+0.39), IO: 2.54 (+0.02), NXTD: 2.70 (+0.04), COVS: 2.47 (+0.11), SZMK: 6.53 (+0.10)
RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 51.50 (-0.66), TSRO: 38.49 (-0.83), HRTX: 10.29 (+0.39), RDHL: 12.69 (+0.04), GWPH: 78.09 (+1.70), OPK: 13.80 (-0.28), GALE: 1.68 (+0.06)
Heron Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Tue Dec 02, 7:01AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014 at 2:10 p.m. ET in New York City.
HRTX: 10.29 (+0.39)
Heron Therapeutics beats 3Q profit forecasts
Automated Insights - Thu Nov 06, 9:07AM CST
REDWOOD CITY, Calif. (AP) _ Heron Therapeutics Inc. (HRTX) on Thursday reported a loss of $19.2 million in its third quarter.
HRTX: 10.29 (+0.39)
Heron Therapeutics Discloses New Proprietary Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV
Business Wire - Thu Nov 06, 7:10AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today disclosed a development program for a P/neurokinin-1 (NK1) receptor antagonist, which is used in the prevention of both acute- and delayed-onset chemotherapy induced nausea and vomiting (CINV). NK1 receptor antagonists are administered in combination with a 5-HT3 receptor antagonist for the prevention of CINV. Heron Therapeutics' lead investigational product candidate, SUSTOL(R) (granisetron injection, extended release), is an extended release 5-HT3 receptor antagonist being developed for the prevention of both acute- and delayed-onset CINV.
HRTX: 10.29 (+0.39)
Heron Therapeutics Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights
Business Wire - Thu Nov 06, 7:02AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today reported third quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
HRTX: 10.29 (+0.39)
Heron Therapeutics hires Esme C. Smith as VP
M2 - Tue Aug 26, 6:55AM CDT
Pharmaceutical company Heron Therapeutics (NasdaqCM:HRTX) revealed on Monday the appointment of Esme C. Smith as its vice president, general counsel and secretary.
HRTX: 10.29 (+0.39)
Heron Therapeutics Appoints Esme C. Smith as Vice President, General Counsel and Secretary
Business Wire - Mon Aug 25, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, today announced that Esme C. Smith will join the Company as Vice President, General Counsel and Secretary, effective today. Ms. Smith will report to Barry D. Quart, Pharm.D., Heron's Chief Executive Officer.
HRTX: 10.29 (+0.39)
Heron Therapeutics Announces Second Quarter and Year-to-Date 2014 Financial Results
Business Wire - Mon Aug 04, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today reported second quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
HRTX: 10.29 (+0.39)
4 Stocks Under $10 Making Big Moves
at The Street - Wed Jul 30, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
HRTX: 10.29 (+0.39), ACI: 1.19 (+0.02), CNAT: 5.92 (+0.10), IKGH: 1.13 (+0.01)
Heron Therapeutics closes public offering of common stock at USD11.75 per share
M2 - Tue Jul 01, 3:00AM CDT
Pharmaceutical company Heron Therapeutics (NasdaqCM:HRTX) reported on Monday the completion of its public offering of 4,751,358 shares of common stock at USD11.75 per share.
HRTX: 10.29 (+0.39)
Heron Therapeutics, Inc. Closes Underwritten Offering of Common Stock
Business Wire - Mon Jun 30, 12:30PM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced closing of its underwritten public offering of 4,751,358 shares of common stock at a public offering price of $11.75 per share. As a component of the offering, in lieu of common stock, Heron Therapeutics, Inc. also offered and sold to certain existing large investors pre-funded warrants to purchase up to an aggregate of 600,000 shares of common stock at a purchase price of $11.74 per warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. Gross offering proceeds to Heron Therapeutics, Inc. are approximately $63 million before deducting underwriting discounts and commissions and offering expenses payable by Heron Therapeutics, Inc.
HRTX: 10.29 (+0.39)
Heron Therapeutics (HRTX) in Focus: Stock Falls 8.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:51AM CDT
Heron Therapeutics saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell almost 9% on the day.
HRTX: 10.29 (+0.39), AERI: 27.91 (+0.14), ARIA: 7.35 (+0.45)
Heron Therapeutics to complete Phase 1 clinical study of HTX-011 for post-operative pain in Q1 and begin Phase 1b/2 studies in surgical patients in Q2
M2 - Thu Feb 12, 4:51AM CST
Biotechnology company Heron Therapeutics (NasdaqCM:HRTX) disclosed on Wednesday the launch of a Phase 1 clinical trial of HTX-011 for the treatment of post-operative pain.
HRTX: 10.29 (+0.39)
Heron Therapeutics Initiates Phase 1 Clinical Study of HTX-011 for the Treatment of Post-Operative Pain
Business Wire - Wed Feb 11, 7:02AM CST
---Phase 1b/2 studies in surgical patients to start in second quarter
HRTX: 10.29 (+0.39)
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 10, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
LGCY: 13.35 (+0.51), AMKR: 8.90 (-0.02), EPRS: 7.67 (+0.67), MFLX: 14.99 (+0.16), MGPI: 14.00 (-0.39), GFN: 9.20 (+0.25), EGLT: 10.60 (+0.58), HRTX: 10.29 (+0.39), PFMT: 6.02 (-0.02), ACHN: 10.89 (-0.20), AGIO: 118.55 (+0.11), QLYS: 47.95 (+1.46), YDLE: 13.07 (+1.14), CBMG: 24.32 (-1.17)
Heron Therapeutics to Present at the Leerink Partners 2015 Global Healthcare Conference
Business Wire - Tue Feb 03, 7:02AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Leerink Partners 2015 Global Healthcare Conference on Wednesday, February 11, 2015 at 8:50 a.m. ET in New York City.
HRTX: 10.29 (+0.39)
Medical chief bids adieu at Heron
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 3:56PM CST
HRTX: 10.29 (+0.39)
Global CINV Existing and Pipeline Drugs (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) Market 2014 - 2020
M2 - Wed Jan 14, 9:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/8zvsf9/cinv_existing_and) has announced the addition of the "CINV Existing and Pipeline Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The approval of new drugs such as rolapitant and SUSTOL (APF-530) would also drive the growth of the CINV drugs market during the forecast period from 2014 to 2020. These pipeline drugs have shown better efficacy than existing drugs during their clinical study. Therefore, the anticipated launch of these more efficacious pipeline drugs during the projected period is likely to encourage physicians to prescribe these new drugs over existing drugs. H owever, the patent expiry of leading drugs Aloxi and Emend are expected to have significant impact on the revenue of overall CINV drugs market during the forecast period from 2014 to 2020. North America was the largest regional market for CINV drugs in 2013 in terms of revenue and is expected to retain its position throughout the forecast period, primarily due to the anticipated approval of rolapitant and SUSTOL in 2015 and 2016, respectively. Europe represented the second largest market for CINV drugs after North America in 2013. The launch of CINV pipeline drugs in Europe is expected to be a year later than in North America, given the delays on the past launches of CINV drugs such as Aloxi and Emend. The high incidence of various types of cancer in Asia-Pacific and Rest of the World (RoW) represents both these regions as potential markets for CINV drugs. The economic emergence of countries such as India and China, along with their continuously improving health care infrastructure, is expected to play a key role in driving the CINV market growth in Asia-Pacific region. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global CINV Existing and Pipeline Drugs Market Overview Chapter 4 Global CINV Existing and Pipeline Drugs Market Revenue, by Major Drugs, 2012 - 2020 (USD Million) Chapter 5 Global CINV Existing and Pipeline Drugs Market Revenue, by Geography, 2012 - 2020 (USD Million) Chapter 6 Competitive Landscape Chapter 7 Company Profiles - GlaxoSmithKline plc - Helsinn Holding S.A. - Heron Therapeutics, Inc. - Merck & Co., Inc. - Tesaro, Inc. For more information visit http://www.researchandmarkets.com/research/8z...isting_and
TSRO: 38.49 (-0.83), HRTX: 10.29 (+0.39), MRK: 58.81 (-0.07), GSK: 47.94 (+1.99)
Conkwest Appoints Robert Rosen and Henry Ji to its Board of Directors
Business Wire - Mon Dec 29, 1:40PM CST
Conkwest, Inc. (the Natural Killer Cell Company of the West), an immuno-oncology company developing Neukoplast(TM) (NK-92(TM)), a proprietary Natural Killer (NK) cell-line based therapy, announces the appointments of Robert Rosen and Henry Ji, Ph.D. to the Company's Board of Directors. Mr. Rosen is President of Heron Therapeutics (NASDAQ:HRTX) and Dr. Ji is co-founder, President and CEO of Sorrento Therapeutics, Inc. (NASDAQ:SRNE).
HRTX: 10.29 (+0.39), LJPC: 18.79 (unch), SRNE: 11.41 (+0.56)
5 Stocks Under $10 Setting Up to Trade Higher: Covisint and More
at The Street - Thu Dec 11, 11:46AM CST
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
HRTX: 10.29 (+0.39), IO: 2.54 (+0.02), NXTD: 2.70 (+0.04), COVS: 2.47 (+0.11), SZMK: 6.53 (+0.10)
RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 51.50 (-0.66), TSRO: 38.49 (-0.83), HRTX: 10.29 (+0.39), RDHL: 12.69 (+0.04), GWPH: 78.09 (+1.70), OPK: 13.80 (-0.28), GALE: 1.68 (+0.06)
Heron Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Tue Dec 02, 7:01AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014 at 2:10 p.m. ET in New York City.
HRTX: 10.29 (+0.39)
Heron Therapeutics beats 3Q profit forecasts
Automated Insights - Thu Nov 06, 9:07AM CST
REDWOOD CITY, Calif. (AP) _ Heron Therapeutics Inc. (HRTX) on Thursday reported a loss of $19.2 million in its third quarter.
HRTX: 10.29 (+0.39)
Heron Therapeutics Discloses New Proprietary Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV
Business Wire - Thu Nov 06, 7:10AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today disclosed a development program for a P/neurokinin-1 (NK1) receptor antagonist, which is used in the prevention of both acute- and delayed-onset chemotherapy induced nausea and vomiting (CINV). NK1 receptor antagonists are administered in combination with a 5-HT3 receptor antagonist for the prevention of CINV. Heron Therapeutics' lead investigational product candidate, SUSTOL(R) (granisetron injection, extended release), is an extended release 5-HT3 receptor antagonist being developed for the prevention of both acute- and delayed-onset CINV.
HRTX: 10.29 (+0.39)
Heron Therapeutics Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights
Business Wire - Thu Nov 06, 7:02AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today reported third quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
HRTX: 10.29 (+0.39)
Heron Therapeutics hires Esme C. Smith as VP
M2 - Tue Aug 26, 6:55AM CDT
Pharmaceutical company Heron Therapeutics (NasdaqCM:HRTX) revealed on Monday the appointment of Esme C. Smith as its vice president, general counsel and secretary.
HRTX: 10.29 (+0.39)
Heron Therapeutics Appoints Esme C. Smith as Vice President, General Counsel and Secretary
Business Wire - Mon Aug 25, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, today announced that Esme C. Smith will join the Company as Vice President, General Counsel and Secretary, effective today. Ms. Smith will report to Barry D. Quart, Pharm.D., Heron's Chief Executive Officer.
HRTX: 10.29 (+0.39)
Heron Therapeutics Announces Second Quarter and Year-to-Date 2014 Financial Results
Business Wire - Mon Aug 04, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today reported second quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
HRTX: 10.29 (+0.39)
4 Stocks Under $10 Making Big Moves
at The Street - Wed Jul 30, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
HRTX: 10.29 (+0.39), ACI: 1.19 (+0.02), CNAT: 5.92 (+0.10), IKGH: 1.13 (+0.01)
Heron Therapeutics closes public offering of common stock at USD11.75 per share
M2 - Tue Jul 01, 3:00AM CDT
Pharmaceutical company Heron Therapeutics (NasdaqCM:HRTX) reported on Monday the completion of its public offering of 4,751,358 shares of common stock at USD11.75 per share.
HRTX: 10.29 (+0.39)
Heron Therapeutics, Inc. Closes Underwritten Offering of Common Stock
Business Wire - Mon Jun 30, 12:30PM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced closing of its underwritten public offering of 4,751,358 shares of common stock at a public offering price of $11.75 per share. As a component of the offering, in lieu of common stock, Heron Therapeutics, Inc. also offered and sold to certain existing large investors pre-funded warrants to purchase up to an aggregate of 600,000 shares of common stock at a purchase price of $11.74 per warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. Gross offering proceeds to Heron Therapeutics, Inc. are approximately $63 million before deducting underwriting discounts and commissions and offering expenses payable by Heron Therapeutics, Inc.
HRTX: 10.29 (+0.39)
Heron Therapeutics (HRTX) in Focus: Stock Falls 8.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:51AM CDT
Heron Therapeutics saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell almost 9% on the day.
HRTX: 10.29 (+0.39), AERI: 27.91 (+0.14), ARIA: 7.35 (+0.45)
